# Phase III Clinical Study of Cetirizine Hydrochloride Injection in Treatment of Acute Urticaria

> **NCT06819774** · PHASE3 · RECRUITING · sponsor: **Shandong New Time Pharmaceutical Co., LTD** · enrollment: 284 (estimated)

## Conditions studied

- Acute Urticaria

## Interventions

- **DRUG:** Cetirizine Hydrochloride Injection
- **DRUG:** Diphenhydramine Hydrochloride Injection

## Key facts

- **NCT ID:** NCT06819774
- **Lead sponsor:** Shandong New Time Pharmaceutical Co., LTD
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-04-22
- **Primary completion:** 2025-08
- **Final completion:** 2025-08
- **Target enrollment:** 284 (ESTIMATED)
- **Last updated:** 2025-02-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06819774

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06819774, "Phase III Clinical Study of Cetirizine Hydrochloride Injection in Treatment of Acute Urticaria". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT06819774. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*